A Small Analysis of Abiraterone Responses in African American Men with Metastatic Castration Resistant Prostate Cancer

Presented at ASCO GU by Stolten and colleagues was abstract 244 that described the responses African American men had to abiraterone (Zytiga) in a retrospective cohort study of men seen at a single institution.  Stolten included differences in the men including their age at diagnosis, prior enzalutamide (Xtandi) and/or docetaxel (chemotherapy) use, as well as [...]

REVIEW – Statins Boost Abiraterone (Zytiga) Activity in Prostate Cancer

Another piece of information from the recent ASCO GU conference in San Francisco Researchers have found that adding statin drugs may prolong the sensitivity of abiraterone acetate (Zytiga) in men with castration-resistant prostate cancer (CRPC) To assess the effect of statins on abiraterone therapy, Dr Harshman, of the Lank Center for Genitourinary Oncology at Dana-Farber [...]

Initial Gleason Score Does Not Impact Abiraterone (Zytiga) Benefit in Prostate Cancer

Clinical trials have shown that there is an overall survival and radiographic progression-free survival benefit derived from abiraterone acetate (Zytiga) in the treatment of men with metastatic castration resistant prostate cancer (mCRPC). A new retrospective study published online, ahead of print, shows this trend is true regardless of a man's Gleason score at diagnosis, despite [...]

On The Horizon – Tests That Can Inform Us If A Drug Will Work Before We Take The Drug

We have become very fortunate over the last 6 years because our arsenal of potential drugs to treat advanced, metastatic prostate cancer has grown. All of our new drugs extend life and most offer palliation of pain. As I have discussed in prior posts we are still in a quandary about how best to sequence [...]

Abiraterone Is Effective In Men Over 75 Years Who Are Chemotherapy-Naive And Have mCRPC

We know that Abiraterone (Zytiga) extends life, but we also know that its side effects can be harsh, especially in elderly men (men over 75 years). We also know that men with metastatic, castrate resistant prostate cancer (mCRPC) have a limited potential life expectancy. Given these facts, it is important to know if, despite being [...]

How We Know What Drugs Might Work In Combination With Each Other – Bringing The Next Big Breakthrough in Prostate Cancer Treatment

Many of the posts that I have written discussed the need for evaluating our current advanced prostate cancer drugs in both combinations and their sequencing. We have a number of new drugs, but we don’t understand how best to sequence them, or whether or not some drugs would do better and extend life by taking [...]

Predicting Who Will Have A Positive Result From Abiraterone (Zytiga) In Men With Metastatic Castrate Resistant Prostate Cancer

We have many new drugs to treat metastatic castrate resistant prostate cancer (mCRPC), but not all men have a positive result to each of the drug. Understanding who might obtain a positive result to a specific drug prior giving it will save both the individual man and society time and money. Understanding this it becomes [...]

Detecting Prostate Cancer Cells in Blood Can Give An Early Warning of Treatment Failure and Shorten Clinical Trials

There is more evidence that the blood test used to count the number of cells circulating in the blood and shed from prostate tumors (circulating tumor cells or CTCs) can indicate whether a treatment is working or not working. A major new study showed that the number of these circulating tumor cells in the blood [...]

*After the Failure of Docetaxel Is There A Best Sequence For Other Treatments?: Results of an Italian Multicenter Study

As we all know there are now a number of new drugs available to treat castrate resistant metastatic prostate cancer (mCRPC). The availability of these new drugs (abiraterone acetate aka Zytiga, cabazitaxel aka Jevtana, and enzalutamide aka Xtandi) for use in men with mCRPC after the failure of chemotherapy (with docetaxel) has opened a number [...]

Long-Term Results of COU-AA-302 Show Abiraterone (Zytiga) Has A Survival Benefit

When the FDA approved Abiraterone with prednisone (Zytiga) in the pre-chemotherapy stage they approved it after an interim analysis of data was performed of the phase III clinical trial (COU-AA-302), The analysis was performed by an independent data monitoring committee that found a significant difference in radiographic progression-free survival (scans that showed no tumor progression [...]

Go to Top